On March 12, 2025, Genom Life Health Holding Group ("GENOMBIO") emerged as a spotlight at the recently concluded Beauty Expo under the theme "Empowering a Healthy Future with Cell Technology," unveiling its full-chain innovations. During the event, Dr. Li Liang, Chairman and President of GENOMBIO, was invited for an exclusive interview by Director Gao, Producer of CCTV’s flagship talk show, delving into how cell technology is reshaping the health industry ecosystem.
As a leading enterprise in China’s biopharmaceutical sector, GENOMBIO has established a comprehensive industrial chain covering cell culture reagents, medical devices, stem cell therapies, and cell drug R&D through its national high-tech R&D platform. At the expo, GENOMBIO showcased its core products and technical solutions:
Serum-Free Media Series: Including specialized media and cryopreservation solutions for MSC, NK, T, and 293 cells. Renowned for high stability and standardized production, these products are widely adopted in research and clinical fields.
Matrigel & Organoid Technology: As key reagents for 3D cell culture, they facilitate drug screening and disease modeling. Live demonstrations of organoid cultivation attracted numerous research institutions for collaboration.
Health Functional Products: GENOM Health’s "LungShuKang" nano-vesicle solution targets respiratory wellness, while Boyaotang’s "Alcohol Relief Decoction" blends traditional medicinal food concepts with modern technology for liver protection, epitomizing "Tech + Tradition" fusion innovation.
GENOM Health captivated audiences with its innovative health management programs, highlighting advancements in cell technology, regenerative medicine, and personalized health solutions. The brand also debuted "Dr.High," a dedicated service for reproductive health.
Cell Banking: Advanced biopreservation for long-term, reliable cell storage.
Mitochondrial Repair: Activates mitochondrial function to combat age-related energy decline.
Gut Microbiota Transplantation: Rebuilds healthy microbial ecosystems to improve overall wellness.
Blood Purification: Efficient detoxification therapy to eliminate toxins and prevent chronic diseases.
Precision Cell Gene Testing: Leverages cutting-edge sequencing to analyze genetic risks and tailor preventive strategies.
The newly launched "Dr.High" brand introduced specialized care programs for reproductive cell vitality and hormonal balance, filling a niche market gap.
Dr. Li emphasized in the CCTV interview: "GENOMBIO’s mission is ‘Guarding Life Health with Cell Technology.’ We aim to deliver end-to-end health management—prevention, intervention, and restoration—making cell technology accessible to all."
GENOMBIO’s booth received over 1,000 professional visitors daily, with on-site orders for media reagents and health programs exceeding expectations. Distributors noted: "GENOM’s portfolio balances scientific depth and market adaptability, especially its impressive cell therapy capabilities."
In the CCTV feature, Dr. Li outlined GENOMBIO’s strategic roadmap:
Tech Breakthroughs: Scaling investment in organoids and stem cell drugs to deepen 2025 R&D initiatives.
Industrial Convergence: Bridging beauty, healthcare, and wellness sectors to unlock cell tech potential in anti-aging and skin repair.
Global Vision: Expanding into neighboring markets to bring China’s cell innovations worldwide.
Founded in 2002 and headquartered in ZJU Zijing Science Town, Hangzhou, Genom Life Health Holding Group is a national high-tech enterprise integrating R&D, production, sales, and technical services across the biopharmaceutical ecosystem—including cell banking, biological reagents/consumables, cell therapy drugs, exosomes, and organoids. Upholding the mission of "Guarding Life Health with Cell Technology" and the vision to build a "Leading Whole-Cell Industry Chain Brand," the group embraces core values of "Customer First, Striving as Foundation, Unity, and Co-Creation." It continues advancing cell technology industrialization to drive innovation in the health industry.